MedTrace Logo

A Study of ABTL0812 in Pancreatic Cancer

NCT03417921 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-01

No results posted yet for this study

Summary

A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy.

Conditions

Interventions

DRUG

ABTL0812

ABTL0812 in combination with gemcitabine and nab-paclitaxel

DRUG

Gemcitabine and nab-paclitaxel

Gemcitabine and nab-paclitaxel as standard pattern

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Ability Pharmaceuticals SL

    lead INDUSTRY

Principal Investigators

  • Carles Domènech, PhD · Ability Pharmaceuticals SL

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2023-04-26
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417921 on ClinicalTrials.gov